72
13
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13208 |
TrkA-IN-1
|
Trk receptor | Tyrosine Kinase/Adaptors |
TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity. | |||
T40294 |
ITK/TRKA-IN-1
|
||
ITK/TRKA-IN-1 is a chemical compound that functions as a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA). With an IC50 value of 1.0 nM, it effectively inhibits the activity of ITK, while demonstrating a remarkable 96% inhibition of TRKA. | |||
T73307 |
TrkA-IN-4
|
||
TrkA-IN-4 是一种有效和具有口服活性的 TrkA 变构抑制剂,是TrkA-IN-3 的前药。TrkA-IN-4 显示出有效的抗伤害作用。 | |||
T73306 | TrkA-IN-3 | ||
TrkA-IN-3 是一种有效和亚选择性的TrkA 变构抑制剂,IC50值为 22.4 nM。TrkA-IN-3 对TrkA 的选择性超过TrkB 和TrkC8000 倍。TrkA-IN-3 可用于研究疼痛。 | |||
T62801 | FLT3/TrKA-IN-1 | ||
FLT3/TrKA-IN-1 是一种有效的 FLT3/TrKA 双激酶抑制剂,能够作用于 FLT3 (IC50: 43.8 nM)、FLT3-ITD (IC50: 97.2 nM)、FLT3-TKD (IC50: 92.5 nM) 和 TrKA (IC50: 23.6 nM)。FLT3/TrKA-IN-1 能够将细胞周期阻滞在 G0/G1 期,并诱导细胞凋亡 (apoptosis),具有抗增殖作用。FLT3/TrKA-IN-1 具有潜力进行急性髓性白血病 (AML) 的研究。 | |||
T16766 |
Ro 08-2750
|
||
Ro 08-2750 是一种非肽和可逆的神经生长因子 (NGF) 抑制剂,与 NGF 结合,IC50 约为 1 µM。它是一种选择性 MSI RNA 结合活性抑制剂,IC50 为 2.7 μM。它选择性抑制 NGF 与 p75NTR 的结合,而不是 TRKA。 | |||
T12731 |
RIPK1-IN-7
|
RIP kinase | Apoptosis; NF-κB |
RIPK1-IN-7 是一种选择性有效的 RIPK1 抑制剂,Kd 值为 4 nM,IC50值为 11 nM。在实验性 B16 黑色素瘤肺转移模型中表现出优异的抗转移活性。 | |||
T9123 |
DS-1205
|
TAM Receptor | Tyrosine Kinase/Adaptors |
DS-1205b free base 是有效的AXL 激酶选择性抑制剂,IC50为 1.3 nM。它对MER,MET 和TRKA 也有抑制作用,IC50分别为 63、104 和 407 nM。 它可以抑制细胞迁移和肿瘤生长。 | |||
T6712 |
Tyrphostin AG 879
AG 879 |
Apoptosis; EGFR; Trk receptor; HER; PDGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tyrphostin AG 879 (AG 879) 是一种抑制TrKA 磷酸化的酪氨酸激酶抑制剂,IC50为 10 μM。它还是一种选择性ErbB2酪氨酸激酶抑制剂,IC50为 1 μM,具有抗癌活性。 | |||
T4349 |
Sitravatinib
MG516,MGCD516 |
Discoidin Domain Receptor (DDR); VEGFR; FLT; Trk receptor; TAM Receptor; c-Kit; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Sitravatinib (MGCD516) 是一种有口服活性的受体酪氨酸激酶抑制剂。它单独使用即具有有效的抗肿瘤功效,且通过促进抗肿瘤免疫微环境增强了 PD-1 阻断的活性。 | |||
T0678 |
Amitriptyline hydrochloride
Amitriptyline HCl,Tryptizol,盐酸阿米替林,Domical,Annoyltin |
Trk receptor; Sigma receptor; 5-HT Receptor; Serotonin Transporter; Sodium Channel; Adrenergic Receptor; AChR; Norepinephrine; Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Membrane transporter/Ion channel; Neuroscience; Tyrosine Kinase/Adaptors |
Amitriptyline hydrochloride (Annoyltin) 是血清素再摄取转运体和去甲肾上腺素再摄取转运体抑制剂,还与多巴胺再摄取转运体结合,其Ki 为 2.58 μM。它也抑制肾上腺素能受体、毒蕈碱受体、组胺受体、5-羟色胺受体。它是TrkA 和TrkA 受体的激动剂,具有强神经营养活性和有抗抑郁作用。 | |||
T39266 |
hTrkA-IN-1
|
||
hTrkA-IN-1 is a potent and orally active inhibitor of TrkA kinase with an IC 50 of 1.3 nM, compound 2.hTrkA-IN-1 can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al. | |||
T63223 | hTrkA-IN-2 | ||
hTrkA-IN-2 是选择性的 hTrkA 变构抑制剂(IC50: 3.9 nM)。 | |||
T9292 |
ALE-0540
ALE0540 |
Others; Trk receptor | Others; Tyrosine Kinase/Adaptors |
ALE-0540是一种非肽类杂环分子,可抑制NGF 与p75和TrkA 的结合,以及TrkA 受体介导的信号转导和生物反应。 | |||
T5635 |
CH7057288
|
Trk receptor | Tyrosine Kinase/Adaptors |
CH7057288 是选择性TRK 抑制剂。 | |||
T14363 |
AZ-23
AZ 23,AZ23 |
Trk receptor | Tyrosine Kinase/Adaptors |
AZ-23是一种 ATP-竞争性的,口服具有活性的 Trk 激酶 A/B/C 抑制剂,IC50值分别为2 nM (TrkA),8 nM (TrkB),24 nM (FGFR1),52 nM (Flt3),55 nM (Ret),84 nM (MuSk),99 nM (Lck)。 | |||
T7435 |
Selitrectinib
LOXO-195 |
Trk receptor | Tyrosine Kinase/Adaptors |
Selitrectinib (LOXO-195) 是二代原肌凝蛋白相关激酶(TRK)抑制剂,能够作用于 TRKA (IC50:0.6 nM) 和 TRKC (IC50<2.5 nM)。 | |||
T14921 |
CE-245677
|
Tie-2; Trk receptor | Tyrosine Kinase/Adaptors |
CE-245677 是可逆的Tie2和TrkA/B 抑制剂,在细胞体系下的IC50值分别为 4.7 和 1 nM。 | |||
T6097 |
GNF-5837
GNF 5837 |
Trk receptor; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
GNF-5837 是一种选择性的,有效的,口服生物利用的泛TRK 抑制剂,在 Ba/F3 细胞中显示出抗增殖作用 (对Tel-TrkC,Tel-TrkB 和Tel-TrkA 的IC50值分别为 7 nM,9 nM 和 11 nM)。 | |||
T6052 |
GW 441756
|
Apoptosis; Raf; Trk receptor; CDK | Apoptosis; Cell Cycle/Checkpoint; MAPK; Tyrosine Kinase/Adaptors |
GW 441756 是一种高特异性神经生长因子受体酪氨酸激酶 a 抑制剂 ,IC50值为 2 nM,可消除 BmK NSPK 诱导神经突生长。 | |||
T4257 |
Belizatinib
TSR-011 |
Trk receptor; ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
Belizatinib (TSR-011) 是可口服的ALK 和 TRKA、TRKB、TRKC 双重抑制剂,对野生型重组 ALK 的IC50值为0.7 nM。 | |||
T3678 |
Entrectinib
RXDX-101,恩曲替尼,NMS-E628 |
Trk receptor; ROS; ALK; Autophagy; ROS Kinase | Angiogenesis; Autophagy; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Entrectinib (RXDX-101) 是一种可口服的 Trk、ROS1和 ALK 抑制剂,具有抗肿瘤和中枢神经活性,抑制 TrkA、TrkB、TrkC、ROS1 和 ALK 的 IC50值分别为 1、3、5、12 和 7 nM。 | |||
T62447 |
Paltimatrectinib
PBI-200,PPI-5278 |
Trk receptor; Tyrosine Kinases | Tyrosine Kinase/Adaptors |
Paltimatrectinib (PBI-200) 是一种高效的酪氨酸激酶 (tyrosine kinase) 抑制剂,具有抗癌活性,抑制肌球蛋白相关激酶 A (TrkA) 。Paltimatrectinib 可用于研究膀胱癌、乳腺癌和结直肠癌。 | |||
T41224 |
CG 428
|
Trk receptor | Tyrosine Kinase/Adaptors |
CG 428 是一种有效的原肌球蛋白受体激酶 (TRK) 降解剂 (uSMITETM),DC50 为 0.36 nM。 CG 428 包含泛 TRK 抑制剂 GNF-8625 的类似物,通过接头连接到 cereblon E3 连接酶配体泊马度胺。 CG 428 对 TRKA 的选择性优于 TRKC 和 TRKB,Kd 为 1nM、4.2 nM 和 28 nM。 CG 428 抑制 KM12 结肠癌细胞的生长,IC50 为 2.9 nM。 | |||
T2349 |
BMS-754807
|
Trk receptor; c-Met/HGFR; IGF-1R | Tyrosine Kinase/Adaptors |
BMS754807 是一种可逆的IGF-1R 抑制剂 (IC50:1.8 nM,Ki<2 nM),也是一种可逆的IR 抑制剂 (IC50:7 nM,Ki<2 nM)。它也抑制 Met (IC50:6 nM),RON (IC50:44 nM),TrkA (IC50:7 nM),TrkB (IC50:4 nM),AurA (IC50:9 nM) 和 AurB (IC50:25 nM) 的活性。 | |||
T4071 |
Repotrectinib
TPX-0005,TPX 0005,TPX0005 |
Trk receptor; ROS; Src; ALK; ROS Kinase | Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Repotrectinib (TPX-0005) 是ROS1(IC50=0.07 nM) 和TRK(对 TRKA/B/C 的IC50=0.83/0.05/0.1 nM) 抑制剂,能够抑制 WTALK(IC50=1.01 nM)。它具有抗癌作用。 | |||
T5995 |
Larotrectinib
LOXO-101,ARRY-470 |
Apoptosis; Trk receptor | Apoptosis; Tyrosine Kinase/Adaptors |
Larotrectinib (LOXO-101)为ATP竞争性、口服选择性抑制剂,针对原肌凝蛋白相关激酶(TRK)家族受体三个亚型(TRKA,B 和C)展现纳摩尔级别的50%抑制浓度。 | |||
T78968 | TRK-IN-23 | Trk receptor | Tyrosine Kinase/Adaptors |
TRK-IN-23 (compound 24b) 是一款口服活性TRK抑制剂,对TRKA、TRKC、TRKAG595R、TRKAF589L和TRKAG667C 表现出高效的抑制作用,其IC50值分别为0.5 nM、9 nM、14 nM、4.4 nM和4.8 nM。此外,TRK-IN-23 能够诱导含有TRKAG595R和TRKAG667C突变的Ba/F3细胞系进行细胞凋亡(apoptosis)。 | |||
T13207 |
PF-06733804
|
Trk receptor | Tyrosine Kinase/Adaptors |
PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect. | |||
T11729 |
JTE-952
|
Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
JTE-952 is a oral, potent active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse | |||
T17169 |
Trk-IN-4
PF-6683324 isomer |
Trk receptor | Tyrosine Kinase/Adaptors |
Trk-IN-4 is an effective pan-Trk inhibitor in cell-based assays (IC50s: 1.9 nM, 2.6 nM, and 1.1 nM for TrkA, TrkB, and TrkC, respectively). | |||
T17000 |
Tavilermide
MIM-D3 |
Trk receptor | Tyrosine Kinase/Adaptors |
Tavilermide is a selective and partial agonist of TrkA or a nerve growth factor mimetic. | |||
T15738 |
Lestaurtinib
KT-5555,CEP-701 |
Others | Others |
Lestaurtinib is a multi-kinase inhibitor. It also has effective activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3, and TrkA (IC50s: 0.9, 3, and less than 25 nM). | |||
T79706 |
TRK-IN-24
|
Trk receptor | Tyrosine Kinase/Adaptors |
TRK-IN-24(compound 10g)是一种针对Trk Receptor的抑制剂,它对TRKA、TRKC、TRKAG595R、TRKAG667C和TRKAF589L的抑制作用的IC50值分别达到5.21、4.51、6.77、1.42和6.13 nM。该化合物在BaF3-CD74-NTRK1G595R和BaF3-CD74-NTRK1G667C异种移植模型中显示出明显的抗肿瘤活性。此外,TRK-IN-24 能有效抑制携带SF、GK、xDFG等单点突变的Ba/F3细胞增殖,其IC50范围为1.43至47.56 nM。 | |||
T62672 | D5261 | ||
D5261 是一个有效的、类型 III 变构的 tropomyosin-related kinase A (TrkA) 抑制剂。 | |||
T29020 |
TSR-011-isomer
TSR011 isomer,TSR-011 isomer,Belizatinib isomer |
||
TSR011-isomer, a TrKA/ALK inhibitor, is used potentially for the treatment of solid tumours and lymphoma. | |||
T73033 | TRK II-IN-1 | Trk receptor | Tyrosine Kinase/Adaptors |
TRKII-IN-1 是一种有效的 II 型TRK抑制剂,对TRKA/B/C及TRKAG667C的IC50分别为3.3、6.4、4.3 和 9.4 nM。此外,TRKII-IN-1 对FLT3、RET和VEGFR2也具有抑制作用,其IC50分别为1.3、9.9 和 71.1 nM。TRKII-IN-1 主要用于TRK驱动的癌症研究。 | |||
T17170 |
PF-06737007
|
Trk receptor | Tyrosine Kinase/Adaptors |
PF-06737007 is an effective inhibitor of pan-Trk in cell-based assays (IC50s: 7.7 nM, 15 nM, and 3.9 nM for TrkA, TrkB, and TrkC, respectively). | |||
T61872 |
Trk-IN-10
|
||
Trk-IN-10 (Compound 14j) is a highly effective inhibitor of TRK, with an IC50 of 0.86 nM against TrkA and 6.92 nM against TrkA G595R. As an RTK, Trk plays a crucial role as a drug target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) demonstrates superior selectivity in inhibiting Trk, which has potential implications for toxicity reduction [1]. | |||
T22318 |
Taletrectinib
DS-6051b,AB-106 |
Trk receptor; ROS; ROS Kinase | Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Taletrectinib (AB-106) 是具有口服活力的、选择性的 ROS1/NTRK 抑制剂。它对重组 ROS1、NTRK1、NTRK2 和 NTRK3 有较强的抑制作用,IC50值分别为 0.207、0.622、2.28 和 0.98 nM。它还抑制 ROS1 G2032R 和其他抗 Crizotinib 的 ROS1 突变体。 | |||
T62341 |
(R)-Larotrectinib
|
||
(R)-Larotrectinib 是一种 TRK 的有效抑制剂,作用于 TrkA (IC50: 28.5 nM)。(R)-Larotrectinib 能够用于研究癌症、炎症以及某些感染性疾病。 | |||
T71121 |
Milciclib maleate
|
||
Milciclib maleate is an inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA). | |||
T12925 |
Sitravatinib malate
MGCD516 malate,MG-516 malate |
TAM Receptor | Tyrosine Kinase/Adaptors |
Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment. | |||
T62093 |
Trk-IN-11
|
||
Trk-IN-11 (Compound 14h) 是一种 TRK 的有效抑制剂,对 TrkA、TrkA G595R 的 IC50 值分别为 1.4 nM、1.8 nM。其中原肌球蛋白受体激酶 (Trk) 是一种受体酪氨酸激酶 (RTK),也是实体瘤中关键的药物靶点。Trk-IN-11对癌症疾病表现出研究潜力。 | |||
T62095 | TRK-IN-19 | ||
TRK-IN-19 (Compound I-10 ) 是一种 TRK 的有效抑制剂,对 TRKA、TRKAG595R 的 IC50 值分别为 1.1 nM、5.3 nM。TRK-IN-19 对癌症疾病表现出潜在的研究价值。 | |||
T39896 |
ALK-IN-9
|
||
ALK-IN-9 (compound 40) is a highly effective ALK inhibitor. It demonstrates remarkable inhibitory activity against cell proliferation, with IC50 values of <0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), and KG-l cell (OP2-FGFR1). | |||
T61443 | Trk-IN-7 | ||
Trk-IN-7 (compound I-6) is a highly potent inhibitor of TRK, exhibiting IC50 values ranging from 0.25-10 nM for TRKA, TRKB, and TRKC, respectively. In addition, Trk-IN-7 demonstrates notable inhibition against EML4-ALK (IC50 <15 nM), as well as ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC50 = 5-50 nM) [1]. | |||
T76813 | Bedinvetmab | ||
Bedinvetmab (ZTS-00508841)为针对神经生长因子(NGF)的犬单克隆抗体(mAb),通过抑制NGF与肌球蛋白原受体激酶A(trkA)及p75神经营养蛋白受体(p75NTR)的相互作用,应用于犬骨关节炎疼痛的研究。 | |||
T63076 |
IHMT-TRK-284
|
||
IHMT-TRK-284 (Compound 34) 是一种有效的、口服具有活力的 type II TRK kinase 抑制剂,能够作用于 TRKA (IC50: 10.5 nM)、TRKB (IC50: 0.7 nM)、TRKC (IC50: 2.6 nM)。IHMT-TRK-284 在激酶组中表现出良好的选择性,体内具有良好的抗肿瘤作用。 | |||
T61712 | Trk-IN-8 | ||
Trk-IN-8, a powerful TRK inhibitor, demonstrates excellent potency against TRKAa, TRKA(G595R), and TRKC(G623R) with IC50 values of 0.42 nM, 0.89 nM, and 1.5 nM, respectively (WO2021115401A1, compound 3) [1]. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01084 |
TrkA Protein, Human, Recombinant (His)
TRK1,TRK,TRKA,neurotrophic tyrosine kinase, recepto... |
Human | HEK293 Cells |
TrkA Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 39.5 kDa and the accession number is P04629-1. | |||
TMPY-01083 |
TrkA Protein, Human, Recombinant (His & hFc)
TRKA,p140-TrkA,MTC,Trk-A,TRK1,TRK,neurotro... |
Human | HEK293 Cells |
TrkA Protein, Human, Recombinant (His & hFc) is expressed in HEK293 mammalian cells with His and hFc tag. The predicted molecular weight is 66 kDa and the accession number is P04629-1. | |||
TMPK-00774 |
TrkA Protein, Human, Recombinant (aa 33-417, His)
TrkAI,TrkA I,Trk-A,TRKA,NTRK1,MTC... |
Human | HEK293 Cells |
TrkA, a tyrosine kinase receptor, is an essential component of the nerve growth factor (NGF) response pathway. The binding of NGF to the receptor induces receptor autophosphorylation and activation of intracellular signaling pathways, resulting in diverse biological effects. | |||
TMPY-03536 |
TrkA Protein, Mouse, Recombinant (His)
neurotrophic tyrosine kinase, receptor, type 1,trk,TrkA<... |
Mouse | HEK293 Cells |
TrkA Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 43.7 kDa and the accession number is Q3UFB7. | |||
TMPY-01760 |
TrkA Protein, Human, Recombinant (aa 194-413, His)
neurotrophic tyrosine kinase, receptor, type 1,MTC,Trk-A,p14... |
Human | HEK293 Cells |
TrkA Protein, Human, Recombinant (aa 194-413, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26 kDa and the accession number is P04629-1. | |||
TMPY-03470 |
TrkA Protein, Mouse, Recombinant (hFc)
TrkA,C80751,neurotrophic tyrosine kinase, receptor,... |
Mouse | HEK293 Cells |
TrkA Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 69.2 kDa and the accession number is Q3UFB7. | |||
TMPY-01759 |
TrkA Protein, Human, Recombinant (aa 285-413, His)
neurotrophic tyrosine kinase, receptor, type 1,p140-TrkA... |
Human | E. coli |
TrkA Protein, Human, Recombinant (aa 285-413, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 15.1 kDa and the accession number is P04629-1. | |||
TMPY-03711 |
TrkA Protein, Canine, Recombinant (hFc)
neurotrophic tyrosine kinase, receptor, type 1 |
Canine | HEK293 Cells |
TrkA Protein, Canine, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 42.3 kDa and the accession number is XP_851619.3. | |||
TMPY-06967 |
TrkA Protein, Cynomolgus, Recombinant (His)
neurotrophic tyrosine kinase, receptor, type 1 |
Cynomolgus | HEK293 Cells |
TrkA Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 43.95 kDa and the accession number is XP_005541454.3. | |||
TMPY-04285 |
TrkA Protein, Rat, Recombinant (His)
neurotrophic tyrosine kinase, receptor, type 1 |
Rat | HEK293 Cells |
TrkA Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 43.7 kDa and the accession number is A6J617. | |||
TMPY-04663 |
TrkA Protein, Rabbit, Recombinant (His)
neurotrophic tyrosine kinase, receptor, type 1 |
Rabbit | HEK293 Cells |
TrkA Protein, Rabbit, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 43.4 kDa and the accession number is XP_008262512.1. | |||
TMPY-03560 |
TrkA Protein, Rat, Recombinant (hFc)
neurotrophic tyrosine kinase, receptor, type 1 |
Rat | HEK293 Cells |
TrkA Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 69.2 kDa and the accession number is P35739. | |||
TMPY-03712 |
TrkA Protein, Canine, Recombinant (His)
neurotrophic tyrosine kinase, receptor, type 1 |
Canine | HEK293 Cells |
TrkA Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 16.2 kDa and the accession number is XP_851619.3. |